Aurobindo Pharma is currently trading at Rs. 142.05, up by 11.40 points or 8.73% from its previous closing of Rs. 130.65 on the BSE.
The scrip opened at Rs. 131.10 and has touched a high and low of Rs. 143.35 and Rs. 127.15 respectively. So far 603771 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 204.90 on 07-Jan-2013 and a 52 week low of Rs. 99.65 on 10-Aug-2012.
Last one week high and low of the scrip stood at Rs. 159.00 and Rs. 129.80 respectively. The current market cap of the company is Rs. 4108.99 crore.
The promoters holding in the company stood at 54.76% while Institutions and Non-Institutions held 30.42% and 14.82% respectively.
USFDA has lifted the import alert for non-sterile products manufactured in Aurobindo Pharma‘s Unit-VI cephalosporin facility based in Hyderabad, India, thereby paving the way for resumption of exports of 9 products to the US market. The import alert was imposed earlier in February 2011. Prior to import alert, the Unit was having annual US sales of $ 33 million for the products.
Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
